Chronic kidney disease and atrial fibrillation


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atrial fibrillation (AF) is one of the most frequently encountered and sustained cardiac arrhythmia in clinical practice, including, among patients with chronic kidney disease (CKD). Research evidence suggests that the prevalence and incidence of AF is higher among patients with CKD than in the absence of renal disease, and that the risk of AF increases in parallel with the progression of renal insufficiency. Potential mechanisms of AF in patients with CKD may include increased sympathetic tone, activation of the renin-angiotensin-aldosterone system, myocardial remodeling, various electrolyte disturbances and an increase in C-reactive protein levels as a marker of systemic inflammatory response. The co-occurrence of CKD and AF is characterized by a high risk of thromboembolic complications. To date, there has been no reliable evidence on the efficacy and safety of antithrombotic therapy in patients with CKD. Hemodialysis is associated with an increased AF risk. Current evidence on the risk-benefit ratio of anticoagulation therapy in patients on hemodialysis is inconsistent and needs to be further investigated.

Full Text

Restricted Access

References

  1. Голицын С.П., Кропачева Е.С., Майков Е.Б., Миронов Н.Ю., Панченко Е.П.,Соколов С.Ф., Шлевков Н.Б. Диагностика и лечение нарушений ритма сердца и проводимости: руководство по диагностике и лечению аритмий. Кардиологический вестник. 2014; 2(9): 3-43.
  2. Смирнов А.В., Шилов Е.М., Добронравов В.А., Каюков И.Г., Бобкова И.Н., Швецов М.Ю., Цыгин А.Н., Шутов А.М. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. 2012. 51 с.
  3. Сыркин А.Л., Иванов Г.Г., Аксельрод А.С., Буланова Н.А., Попов В.В. Прогнозирование эффективности поддерживающей антиаритмической терапии при пароксизмальной форме фибрилляции предсердий. Кардиология и сердечно-сосудистая хирургия. 2010; 4: 84-87.
  4. Kuîkarni N., Gukathasan N., Sartori S., Baber U. Chronic Kidney Disease and Atrial Fibrillation: A Contemporary Overview. J. Atr. Fibrillation. 2012; 5(1): 62-70.
  5. Voroneanu L., Ortiz A., Nistor I., Covic A. Atrial fibrillation in CKD. Eur. J. Intern. Med. 2016; 33: 3-13. doi: 10.1016/j.ejim.2016.04.007.
  6. Khai P., Edwards N., Lip G., Townend J.N., Ferro C.J. Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. Am. J. Kidney Dis. 2013; 62(3): 615-632. doi: 10.1053/j.ajkd.2013.02.381.
  7. Khouri Y., Stephens T., Ayuba G., Al-Ameri H., Juratli N., McCullough P.A. Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease. J. Atr. Fibrillation. 2015; 7(6): 62-68.
  8. Boriani G., Savelieva I., Dan G., Deharo J.C., Ferro C., Israel C.W., Lane D.A., La Manna G, Morton J., Mitjans A.M., Vos M.A., Turakhia M.P., Lip G.Y. Document reviewers. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015; 17(8): 1169-1196. doi: 10.1093/europace/euv202.
  9. van Marion D.M., Lanters E.A., Wiersma M., Allessie M.A., Brundel B.B., de Groot N.M. Diagnosis and Therapy of Atrial Fibrillation: The Past, The Present and The Future. J. Atr. Fibrillation. 2015; 8(2): 1216.
  10. Nimmo С., Wright M., Goldsmith D. Management of atrial fibrillation in chronic kidney disease: Double trouble. Am. Heart J. 2013; 166: 230-239. doi: 10.1016/j.ahj.2013.05.010.
  11. Reinecke H., Brand E., Mesters R., Schabitz W.R., Fisher M., Pavenstadt H., Breithardt G. Dilemmas in the Management of Atrial Fibrillation in Chronic Kidney Disease. J. Am. Soc. Nephrol 2009; 20: 705-711. doi: 10.1681/ASN.2007111207.
  12. Qamar A., Bhatt D. Stroke Prevention in Atrial Fibrillation in Patients With Chronic Kidney Disease. Circulation. 2016; 133(15): 1512-1515. doi: 10.1161/CIRCULATIONAHA.115.018549.
  13. Shroff G. Renal Function in Patients With Atrial Fibrillation Receiving Anticoagulants The Canaries in the Coal Mine. JAMA Cardiol. 2016; 1(4): 375-376. doi: 10.1001/jamacardio.2016.1258.
  14. Williams E.S., Vivian T.P., Karen C.E. Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. Cardiol J. 2013; 20(4): 439-446. doi: 10.5603/CJ.2013.0104.
  15. Martin S., Johannes R., Marcos D., Marschang H., Sinha A.M., Biggar P., Jung P., Ketteler M., Brachmann J., Rittger H. Relation of recurrence of atrial fibrillation after successful cardioversion to renal function. Am. J. Cardiol. 2010; 105(3): 368-372. doi: 10.1016/j.amjcard.2009.09.037.
  16. Hart R., Eikelboom J., Ingram A., Herzog C.A. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat. Rev. Nephrol. 2012; 8: 569-578. doi: 10.1038/nrneph.2012.160.
  17. Lai H.M., Aronow W.S., Kalen P., Adapa S., Patel K., Goel A., Vinnakota R., Chugh S., Garrick R. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int. J. Nephrol. Renovasc. Dis. 2009; 2: 33-37.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies